Kestra Private Wealth Services LLC Buys 5,027 Shares of Zoetis Inc. (NYSE:ZTS)

Kestra Private Wealth Services LLC boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 6.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 82,692 shares of the company’s stock after acquiring an additional 5,027 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Zoetis were worth $13,473,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZTS. Darwin Wealth Management LLC bought a new stake in Zoetis during the third quarter worth about $31,000. First Personal Financial Services acquired a new stake in Zoetis during the 3rd quarter valued at $33,000. Capital Performance Advisors LLP acquired a new position in Zoetis in the third quarter worth $33,000. Dunhill Financial LLC grew its holdings in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the last quarter. Finally, Fortitude Family Office LLC raised its position in Zoetis by 1,387.5% in the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after purchasing an additional 222 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on ZTS. Stifel Nicolaus dropped their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group initiated coverage on shares of Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective on the stock. Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. Finally, Morgan Stanley dropped their price objective on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Zoetis has an average rating of “Buy” and a consensus target price of $215.00.

Zoetis Price Performance

NYSE:ZTS opened at $171.37 on Friday. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The company has a market cap of $77.32 billion, a P/E ratio of 32.21, a P/E/G ratio of 2.77 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The stock’s 50-day simple moving average is $169.26 and its 200 day simple moving average is $179.22.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.17%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is presently 37.59%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.